All Benjamin Moutier (Senior Vice President of Vaccines and Immune Therapies - AstraZeneca) articles

  • Abstract,Vertical,Illustration,Of,Targeting,Cancer,Cell,Made,Of,Glowing
    Article

    New fixed-duration therapy could reshape CLL care

    2025-05-28T09:00:10Z

    Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment ...